JP7884456B2 - 遺伝子治療 - Google Patents

遺伝子治療

Info

Publication number
JP7884456B2
JP7884456B2 JP2022554473A JP2022554473A JP7884456B2 JP 7884456 B2 JP7884456 B2 JP 7884456B2 JP 2022554473 A JP2022554473 A JP 2022554473A JP 2022554473 A JP2022554473 A JP 2022554473A JP 7884456 B2 JP7884456 B2 JP 7884456B2
Authority
JP
Japan
Prior art keywords
viral vector
seq
promoter
aav
col4a5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517934A5 (cg-RX-API-DMAC7.html
JP2023517934A (ja
Inventor
シュミット,ドミニク
クズムク,ヴァレリイア
サレーム,モイン
ウェルシュ,ギャビン
Original Assignee
ザ ユニバーシティ オブ ブリストル
シンコナ アイピー ホールドコ(3) リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ オブ ブリストル, シンコナ アイピー ホールドコ(3) リミテッド filed Critical ザ ユニバーシティ オブ ブリストル
Publication of JP2023517934A publication Critical patent/JP2023517934A/ja
Publication of JP2023517934A5 publication Critical patent/JP2023517934A5/ja
Priority to JP2026037543A priority Critical patent/JP2026116914A/ja
Application granted granted Critical
Publication of JP7884456B2 publication Critical patent/JP7884456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022554473A 2020-03-12 2021-03-12 遺伝子治療 Active JP7884456B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026037543A JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003618.2 2020-03-12
GBGB2003618.2A GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy
PCT/GB2021/050633 WO2021181118A1 (en) 2020-03-12 2021-03-12 Gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026037543A Division JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Publications (3)

Publication Number Publication Date
JP2023517934A JP2023517934A (ja) 2023-04-27
JP2023517934A5 JP2023517934A5 (cg-RX-API-DMAC7.html) 2024-03-21
JP7884456B2 true JP7884456B2 (ja) 2026-07-03

Family

ID=70453740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554473A Active JP7884456B2 (ja) 2020-03-12 2021-03-12 遺伝子治療
JP2026037543A Pending JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026037543A Pending JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Country Status (11)

Country Link
US (1) US12589167B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118216A1 (cg-RX-API-DMAC7.html)
JP (2) JP7884456B2 (cg-RX-API-DMAC7.html)
CN (2) CN121950927A (cg-RX-API-DMAC7.html)
AU (1) AU2021234169B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018036A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171232A1 (cg-RX-API-DMAC7.html)
GB (1) GB202003618D0 (cg-RX-API-DMAC7.html)
IL (1) IL296255A (cg-RX-API-DMAC7.html)
MX (1) MX2022011295A (cg-RX-API-DMAC7.html)
WO (1) WO2021181118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
CN116590345B (zh) * 2023-05-06 2024-01-30 北京中医药大学 永生化小鼠足细胞系及其制备方法、分化方法和应用
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309914D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters
GB202309909D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
AU2025218305A1 (en) * 2024-02-07 2026-07-30 Purespring Therapeutics Limited Vectors
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532365A (ja) 2014-07-25 2017-11-02 ゴールドフィンチ バイオファーマ,インク. コラーゲンivの置き換え

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US20060281090A1 (en) 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
US20050169914A1 (en) 2003-08-01 2005-08-04 Colgan Sean P. Novel functions for decay accelerating factor (DAF) in inflammation
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
KR101105125B1 (ko) 2007-05-07 2012-01-16 울산대학교 산학협력단 클러스터린을 이용한 체중 조절 장애 관련 질환의 진단, 예방 또는 치료 방법
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
CN108531444A (zh) 2010-08-05 2018-09-14 威斯康星校友研究基金会 用于人多能细胞培养的简化基础培养基
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
KR20190075964A (ko) * 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
CN107011424B (zh) 2017-03-14 2020-07-03 华南师范大学 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用
GB201706808D0 (en) 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3635121A1 (en) 2017-06-02 2020-04-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
CN111788311A (zh) 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
RU2675861C1 (ru) 2017-11-22 2018-12-25 Лев Иосифович Шагам Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта"
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
CN113166208B (zh) * 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
CA3117551A1 (en) 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
RU2714763C1 (ru) 2018-11-08 2020-02-19 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532365A (ja) 2014-07-25 2017-11-02 ゴールドフィンチ バイオファーマ,インク. コラーゲンivの置き換え

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gene Therapy,2001年,8,pp.882-890
Hearing Research,2020年02月,394, 107912,pp.1-13
HUMAN GENE THERAPY,1999年,10,pp.2295-2305
Molecular Therapy-Methods & Clinical Development,2014年,1, 14014,doi:10.1038/mtm.2014.14

Also Published As

Publication number Publication date
CA3171232A1 (en) 2021-09-16
WO2021181118A1 (en) 2021-09-16
JP2026116914A (ja) 2026-07-14
MX2022011295A (es) 2022-11-14
CN115427578A (zh) 2022-12-02
US12589167B2 (en) 2026-03-31
CN121950927A (zh) 2026-05-01
GB202003618D0 (en) 2020-04-29
AU2021234169B2 (en) 2026-08-06
BR112022018036A2 (pt) 2022-11-01
JP2023517934A (ja) 2023-04-27
AU2021234169A1 (en) 2022-10-06
EP4118216A1 (en) 2023-01-18
CN115427578B (zh) 2026-03-17
US20240197917A1 (en) 2024-06-20
IL296255A (en) 2022-11-01

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260623

R150 Certificate of patent or registration of utility model

Ref document number: 7884456

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150